配售股份
Search documents
CMON拟发行最多3.612亿股配售股份 净筹约630万港元
Zheng Quan Shi Bao Wang· 2025-10-20 00:09
Core Viewpoint - CMON plans to issue up to 361.2 million placement shares at a price of HKD 0.018 per share, representing a discount of approximately 14.29% from the closing price of HKD 0.021 on October 17, 2025 [1] Summary by Sections - The total amount raised from the placement is approximately HKD 6.5016 million, with a net estimated amount of around HKD 6.3 million [1] - The company intends to use the net proceeds from the placement entirely for general working capital [1] - The placement shares will account for approximately 16.67% of the enlarged issued share capital of the company [1]
正力新能拟折价约7.89%配售合共4592.1万股新H股
Zhi Tong Cai Jing· 2025-10-17 00:07
Group 1 - The company, Zhengli New Energy (03677), announced a placement agreement with an exclusive placing agent to sell 45.921 million new H-shares at a price of HKD 10.98 per share, representing approximately 3.19% of the issued H-shares as of the announcement date [1] - The placement price of HKD 10.98 per share is at a discount of about 7.89% compared to the closing price of HKD 11.92 on the trading day before the agreement [1] - If all shares are fully subscribed, the total proceeds from the placement will amount to HKD 504 million, with a net amount estimated at HKD 500.4 million, resulting in a net issue price of approximately HKD 10.90 per share [1] Group 2 - The net proceeds from the placement will enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term sustainable development [2] - Approximately 70% of the net proceeds will be allocated to support the construction, equipment purchase, and contingency costs related to the second phase of the new production facility in Changshu [2] - About 10% of the net proceeds will be used for the construction of a pilot line for all-solid-state batteries, another 10% for research and development activities, and the remaining 10% for working capital and general corporate purposes [2]
中联发展控股拟折让约16.27%发行最多1500万股配售股份 净筹约2555万港元
Zhi Tong Cai Jing· 2025-09-30 11:12
Group 1 - The company, Zhonglian Development Holdings (00264), has announced a placement agreement to issue up to 15 million shares at a price of HKD 1.75 per share, which represents a discount of approximately 16.27% compared to the closing price of HKD 2.09 on September 30, 2025 [1][2] - The maximum number of shares to be placed corresponds to about 3.25% of the enlarged issued share capital of the company, assuming no changes in the issued share capital during the placement period [1] - The expected net proceeds from the placement, after deducting commissions and related expenses, will be approximately HKD 25.55 million, with a net issue price of about HKD 1.70 per share [2] Group 2 - The company plans to use the net proceeds from the placement for general working capital and to enhance its financial position, with allocations including approximately HKD 6.06 million for materials and equipment related to leather manufacturing and cleaning services, HKD 13.69 million for general operational expenses, HKD 2.94 million for settling outstanding payables, and approximately HKD 2.86 million for new business development opportunities [2]
重塑能源:拟折让14.21%配售新H股,净筹约7830万港元
Xin Lang Cai Jing· 2025-09-25 23:52
9月26日早间,重塑能源在港交所公告,于2025年9月25日(交易时段后),公司与联席配售代理订立配 售协议,据此,联席配售代理有条件同意竭力促使承配人购买583,860股配售股份,配售价为每股配售 股份137.00港元,配售价较H股于2025年9月25日于联交所所报收市价折让约14.21%。假设所有配售股 份均获悉数配售且待交割后,预计配售事项最高所得款项净额约为7830万港元,目前拟按如下方式使 用:约50%将用于通过偿还未偿还银行贷款及租赁负债而优化集团财务结构;约50%将用于一般公司用 途。 ...
友宝在线拟发行至多1.575亿股配售股份
Zheng Quan Shi Bao Wang· 2025-09-22 00:48
Group 1 - The company, Youbao Online, has entered into a placement agreement to issue up to 157.5 million shares at a price of HKD 2.45 per share to at least six institutional professional investors [1] - The shares to be placed represent approximately 19.96% of the issued H shares as of the announcement date and about 18.94% of the total issued shares [1] - The total expected fundraising amount is approximately HKD 386 million, with a net amount of about HKD 383 million [1] Group 2 - The net proceeds from the fundraising will be allocated as follows: 20% for product development, 20% for offline channel expansion, 30% for the purchase of fixed assets (such as vending machines), and 30% for working capital and general corporate purposes [1] - The company's board believes that this placement will enhance the group's financial position, expand the shareholder base, optimize the capital structure, and support sustainable development [1]
友宝在线(02429.HK):拟折让约16.95%发行至多1.575亿股配售股份
Ge Long Hui· 2025-09-21 10:47
假设所有配售股份获悉数配售且已完成,预计配售事项的所得款项总额合共约为3.86亿港元,而预计配 售事项的所得款项净额合共约为3.83亿港元。在此基础上,净配售价将约为每股配售股份2.43港元。配 售事项所得款项净额的约20.0%用于开发基于专有知识产权的商品;配售事项所得款项净额的约20.0% 用于支撑基于专有知识产权的商品的线下销售渠道扩张;配售事项所得款项净额的约30.0%用于购置固 定资产,包括但不限于基于专有知识产权的商品预期销售而增设的自动售货机;配售事项所得款项净额 的约30.0%用于营运资金及其他一般公司用途。 董事们相信,配售事项将有利于增强本集团的流动性和财务状况,扩大本公司股东基础,优化本公司的 资本结构,并支持本公司的健康及可持续发展。 配售事项项下1.575亿股配售股份占截至本公告日期已发行H股数目的约19.96%及已发行股份数目的约 18.94%,及经配发及发行配售股份扩大后的已发行H股数目的约16.64%及已发行股份数目的约15.93% (假设本公司已发行股份数目自本公告日期起至完成配售事项之日为止并无变动)。配售价每股配售股份 2.45港元较H股于2025年9月19日于联交所所报 ...
友宝在线拟折让约16.95%发行至多1.575亿股配售股份
Zhi Tong Cai Jing· 2025-09-21 10:44
配售事项项下1.575亿股配售股份占截至本公告日期已发行H股数目的约19.96%及已发行股份数目的约 18.94%,及经配发及发行配售股份扩大后的已发行H股数目的约16.64%及已发行股份数目的约15.93% (假设本公司已发行股份数目自本公告日期起至完成配售事项之日为止并无变动)。配售价每股配售股份 2.45港元较H股于2025年9月19日于联交所所报的收市价每股H股2.95港元折让约16.95%。 假设所有配售股份获悉数配售且已完成,预计配售事项的所得款项总额合共约为3.86亿港元,而预计配 售事项的所得款项净额合共约为3.83亿港元。在此基础上,净配售价将约为每股配售股份2.43港元。配 售事项所得款项净额的约20.0%用于开发基于专有知识产权的商品;配售事项所得款项净额的约20.0%用 于支撑基于专有知识产权的商品的线下销售渠道扩张;配售事项所得款项净额的约30.0%用于购置固定资 产,包括但不限于基于专有知识产权的商品预期销售而增设的自动售货机;配售事项所得款项净额的约 30.0%用于营运资金及其他一般公司用途。 友宝在线(02429)发布公告,于2025年9月19日,本公司与配售代理订立配售协议, ...
友宝在线(02429)拟折让约16.95%发行至多1.575亿股配售股份
智通财经网· 2025-09-21 10:37
智通财经APP讯,友宝在线(02429)发布公告,于2025年9月19日,本公司与配售代理订立配售协议,本 公司同意委任配售代理,而配售代理同意作为本公司的代理尽最大努力促使不少于6名承配人(将为机构 专业投资者,且彼等及彼等的最终实益拥有人将为独立第三方)按配售价每股配售股份2.45港元认购至 多1.575亿股配售股份。 董事们相信,配售事项将有利于增强本集团的流动性和财务状况,扩大本公司股东基础,优化本公司的 资本结构,并支持本公司的健康及可持续发展。 配售事项项下1.575亿股配售股份占截至本公告日期已发行H股数目的约19.96%及已发行股份数目的约 18.94%,及经配发及发行配售股份扩大后的已发行H股数目的约16.64%及已发行股份数目的约15.93% (假设本公司已发行股份数目自本公告日期起至完成配售事项之日为止并无变动)。配售价每股配售股份 2.45港元较H股于2025年9月19日于联交所所报的收市价每股H股2.95港元折让约16.95%。 假设所有配售股份获悉数配售且已完成,预计配售事项的所得款项总额合共约为3.86亿港元,而预计配 售事项的所得款项净额合共约为3.83亿港元。在此基础上,净配 ...
金石控股集团(01943)拟折让约19.87%配售最多1.5亿股配售股份
智通财经网· 2025-09-05 14:56
Core Viewpoint - Kingstone Holdings Group (01943) announced a placement agreement with a placement agent to issue up to 150 million shares at a price of HKD 0.617 per share, representing a discount of approximately 19.87% from the closing price of HKD 0.77 on the date of the agreement [1] Group 1 - The placement shares represent approximately 13.04% of the enlarged issued share capital of the company [1] - If all placement shares are fully placed, the total gross proceeds and net proceeds (after deducting placement commission and other expenses) will be approximately HKD 92.55 million and HKD 91.02 million, respectively, equating to a net placement price of about HKD 0.607 per share [1] - The company plans to use approximately HKD 67 million (about 73.61% of the net proceeds) for the development of user-side industrial and commercial energy storage projects and upgrading new industrial parks [1] Group 2 - Approximately HKD 24.02 million (about 26.39% of the net proceeds) will be allocated for general working capital, including repayment of shareholder loans and payment of expenses, salaries and benefits, professional fees, rent, management fees, and other costs [1]
歌礼制药:拟折让约9.9%配售5240万股
Ge Long Hui A P P· 2025-08-19 00:29
Core Viewpoint - The company, Gilead Sciences, announced a placement and subscription agreement for the sale of 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]